Home
XNCR
XNCR News

Latest Xencor Inc. (XNCR) News on July 31, 2025

Argus Research

22 days ago

XNCR: Raising target price to $7.00

Argus Research

a month ago

XNCR: Rating decreased to a SELL

Argus Research

2 months ago

XNCR: What does Argus have to say about XNCR?

Argus Research

2 months ago

XNCR: What does Argus have to say about XNCR?

Argus Research

3 months ago

XNCR: What does Argus have to say about XNCR?

Xencor (XNCR) Reports Q1 Loss, Tops Revenue Estimates

Zacks

3 months ago

Xencor (XNCR) Reports Q1 Loss, Tops Revenue Estimates

Associated Press Finance

3 months ago

Xencor: Q1 Earnings Snapshot

Xencor Reports First Quarter 2025 Financial Results

Business Wire

3 months ago

Xencor Reports First Quarter 2025 Financial Results

Argus Research

3 months ago

XNCR: Lowering target price to $9.00

Will Xencor (XNCR) Report Negative Q1 Earnings? What You Should Know

Zacks

3 months ago

Will Xencor (XNCR) Report Negative Q1 Earnings? What You Should Know

Xencor Announces Positive Interim Results From First-in-Human Healthy Volunteer Study of XmAb942, a High-Potency Extended Half-Life Anti-TL1A Antibody, in Development for Treatment of Inflammatory Bowel Disease

Business Wire

3 months ago

Xencor Announces Positive Interim Results From First-in-Human Healthy Volunteer Study of XmAb942, a High-Potency Extended Half-Life Anti-TL1A Antibody, in Development for Treatment of Inflammatory Bowel Disease

Argus Research

3 months ago

XNCR: Raising target price to $11.00

MT Newswires

3 months ago

William Blair Initiates Xencor at Outperform

Argus Research

3 months ago

XNCR: Raising target price to $10.00

Argus Research

3 months ago

Daily – Vickers Top Buyers & Sellers for 04/15/2025

Xencor (XNCR) Upgraded to Buy: Here's Why

Zacks

4 months ago

Xencor (XNCR) Upgraded to Buy: Here's Why

Argus Research

4 months ago

XNCR: Lowering target price to $8.00

Argus Research

4 months ago

XNCR: Lowering target price to $10.00

Argus Research

4 months ago

XNCR: Lowering target price to $12.00

Xencor Appoints Todd Simpson to Board of Directors

Business Wire

5 months ago

Xencor Appoints Todd Simpson to Board of Directors

MT Newswires

5 months ago

Xencor Insider Sold Shares Worth $268,080, According to a Recent SEC Filing

Argus Research

5 months ago

XNCR: What does Argus have to say about XNCR?

MT Newswires

5 months ago

RBC Capital Adjusts Xencor Price Target to $32 From $34, Maintains Outperform - Speculative Risk Rating

MT Newswires

5 months ago

Wedbush Cuts Price Target on Xencor to $31 From $38, Keeps Outperform Rating

Xencor Full Year 2024 Earnings: Beats Expectations

Simply Wall St.

5 months ago

Xencor Full Year 2024 Earnings: Beats Expectations

MT Newswires

5 months ago

Xencor's Q4 Net Loss Widens, Revenue Rises

Xencor (XNCR) Reports Q4 Loss, Tops Revenue Estimates

Zacks

5 months ago

Xencor (XNCR) Reports Q4 Loss, Tops Revenue Estimates

Associated Press Finance

5 months ago

Xencor: Q4 Earnings Snapshot

Xencor Reports Fourth Quarter and Full Year 2024 Financial Results

Business Wire

5 months ago

Xencor Reports Fourth Quarter and Full Year 2024 Financial Results

Argus Research

5 months ago

XNCR: Lowering target price to $15.00

Argus Research

5 months ago

XNCR: What does Argus have to say about XNCR?

Xencor (XNCR) Loses -25.22% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Zacks

6 months ago

Xencor (XNCR) Loses -25.22% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Argus Research

6 months ago

XNCR: Lowering target price to $19.00

Xencor (NASDAQ:XNCR investor five-year losses grow to 50% as the stock sheds US$96m this past week

Simply Wall St.

6 months ago

Xencor (NASDAQ:XNCR investor five-year losses grow to 50% as the stock sheds US$96m this past week

Argus Research

6 months ago

XNCR: Lowering target price to $20.00

Argus Research

6 months ago

XNCR: Raising target price to $21.00

Down -21.69% in 4 Weeks, Here's Why Xencor (XNCR) Looks Ripe for a Turnaround

Zacks

6 months ago

Down -21.69% in 4 Weeks, Here's Why Xencor (XNCR) Looks Ripe for a Turnaround

After Plunging -20.27% in 4 Weeks, Here's Why the Trend Might Reverse for Xencor (XNCR)

Zacks

6 months ago

After Plunging -20.27% in 4 Weeks, Here's Why the Trend Might Reverse for Xencor (XNCR)

Here's Why Xencor (XNCR) is Poised for a Turnaround After Losing -23.68% in 4 Weeks

Zacks

7 months ago

Here's Why Xencor (XNCR) is Poised for a Turnaround After Losing -23.68% in 4 Weeks

Argus Research

7 months ago

XNCR: Lowering target price to $20.00

Xencor (XNCR) Upgraded to Strong Buy: Here's What You Should Know

Zacks

7 months ago

Xencor (XNCR) Upgraded to Strong Buy: Here's What You Should Know

Argus Research

7 months ago

XNCR: What does Argus have to say about XNCR?

Argus Research

7 months ago

XNCR: Rating increased to a HOLD

All You Need to Know About Xencor (XNCR) Rating Upgrade to Buy

Zacks

8 months ago

All You Need to Know About Xencor (XNCR) Rating Upgrade to Buy

MT Newswires

8 months ago

Wells Fargo Initiates Xencor at Overweight With $37 Price Target

Argus Research

8 months ago

XNCR: Lowering target price to $23.00

Wall Street Analysts Think Xencor (XNCR) Could Surge 31.58%: Read This Before Placing a Bet

Zacks

8 months ago

Wall Street Analysts Think Xencor (XNCR) Could Surge 31.58%: Read This Before Placing a Bet

Argus Research

8 months ago

XNCR: Raising target price to $24.00

MT Newswires

8 months ago

Piper Sandler Upgrades Xencor to Overweight, Price Target is $30

Argus Research

8 months ago

XNCR: Raising target price to $23.00

Xencor to Participate at Upcoming Investor Conferences

Business Wire

8 months ago

Xencor to Participate at Upcoming Investor Conferences

MT Newswires

8 months ago

Top Premarket Gainers

Wall Street Analysts Believe Xencor (XNCR) Could Rally 53.53%: Here's is How to Trade

Zacks

8 months ago

Wall Street Analysts Believe Xencor (XNCR) Could Rally 53.53%: Here's is How to Trade

Xencor (XNCR)'s Technical Outlook is Bright After Key Golden Cross

Zacks

9 months ago

Xencor (XNCR)'s Technical Outlook is Bright After Key Golden Cross

MT Newswires

9 months ago

Xencor Insider Sold Shares Worth $1,612,639, According to a Recent SEC Filing

Argus Research

9 months ago

XNCR: Raising target price to $25.00

Xencor, Inc. (NASDAQ:XNCR) Analysts Just Slashed Next Year's Revenue Estimates By 14%

Simply Wall St.

9 months ago

Xencor, Inc. (NASDAQ:XNCR) Analysts Just Slashed Next Year's Revenue Estimates By 14%

Xencor (XNCR) Reports Q3 Loss, Tops Revenue Estimates

Zacks

9 months ago

Xencor (XNCR) Reports Q3 Loss, Tops Revenue Estimates

Associated Press Finance

9 months ago

Xencor: Q3 Earnings Snapshot

Xencor Reports Third Quarter 2024 Financial Results

Business Wire

9 months ago

Xencor Reports Third Quarter 2024 Financial Results

Argus Research

9 months ago

XNCR: What does Argus have to say about XNCR?

Xencor Doses First Subject in Phase 1/2 Study of XmAb®942 in Development for Patients with Inflammatory Bowel Disease

Business Wire

9 months ago

Xencor Doses First Subject in Phase 1/2 Study of XmAb®942 in Development for Patients with Inflammatory Bowel Disease

Does Xencor (XNCR) Have the Potential to Rally 68.16% as Wall Street Analysts Expect?

Zacks

9 months ago

Does Xencor (XNCR) Have the Potential to Rally 68.16% as Wall Street Analysts Expect?

Jazz Pharmaceuticals (JAZZ) Earnings Expected to Grow: Should You Buy?

Zacks

9 months ago

Jazz Pharmaceuticals (JAZZ) Earnings Expected to Grow: Should You Buy?

Xencor (XNCR) Expected to Beat Earnings Estimates: Should You Buy?

Zacks

9 months ago

Xencor (XNCR) Expected to Beat Earnings Estimates: Should You Buy?

State Street Corp's Strategic Reduction in Xencor Inc Holdings

GuruFocus.com

9 months ago

State Street Corp's Strategic Reduction in Xencor Inc Holdings

Wall Street Analysts Predict a 67.2% Upside in Xencor (XNCR): Here's What You Should Know

Zacks

9 months ago

Wall Street Analysts Predict a 67.2% Upside in Xencor (XNCR): Here's What You Should Know

Xencor Presents Preclinical Data on XmAb942, a High-Potency Extended Half-Life Anti-TL1A Antibody, to be Developed for Patients with Inflammatory Bowel Diseases

Business Wire

10 months ago

Xencor Presents Preclinical Data on XmAb942, a High-Potency Extended Half-Life Anti-TL1A Antibody, to be Developed for Patients with Inflammatory Bowel Diseases

Argus Research

10 months ago

XNCR: What does Argus have to say about XNCR?

Xencor Announces Upcoming Change to Board of Directors

Business Wire

10 months ago

Xencor Announces Upcoming Change to Board of Directors

MT Newswires

10 months ago

RBC Raises Price Target on Xencor to $34 From $31, Keeps Outperform, Speculative Risk

MT Newswires

a year ago

Xencor Raises $201.3 Million From Public Offering

Xencor Announces Closing of Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

Business Wire

a year ago

Xencor Announces Closing of Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

Xencor (XNCR) Surges 10.5%: Is This an Indication of Further Gains?

Zacks

a year ago

Xencor (XNCR) Surges 10.5%: Is This an Indication of Further Gains?

MT Newswires

a year ago

Xencor Prices $175 Million Public Stock Offering

Xencor Announces Pricing of $175 Million Public Offering of Common Stock

Business Wire

a year ago

Xencor Announces Pricing of $175 Million Public Offering of Common Stock

MT Newswires

a year ago

Xencor Launching Stock Sale; Shares Lower After-Hours

Xencor Announces Proposed Public Offering of Common Stock

Business Wire

a year ago

Xencor Announces Proposed Public Offering of Common Stock

Xencor Stock Gains 23% on Encouraging Pipeline Advancements

Zacks

a year ago

Xencor Stock Gains 23% on Encouraging Pipeline Advancements

MT Newswires

a year ago

Sector Update: Health Care Stocks Higher Late Afternoon

MT Newswires

a year ago

Sector Update: Health Care Stocks Rise Monday Afternoon

MT Newswires

a year ago

Xencor Shares Rise After 4 New Drug Candidates for Autoimmune, Inflammatory Diseases Announced

Xencor Announces XmAb Drug Candidates in Autoimmune Disease with Near-Term Clinical Plans and Shares Clinical Progress in Early-Stage Oncology Programs

Business Wire

a year ago

Xencor Announces XmAb Drug Candidates in Autoimmune Disease with Near-Term Clinical Plans and Shares Clinical Progress in Early-Stage Oncology Programs

Xencor to Host Research & Development Webcast and Conference Call on Monday, September 9, 2024

Business Wire

a year ago

Xencor to Host Research & Development Webcast and Conference Call on Monday, September 9, 2024

Argus Research

a year ago

XNCR: What does Argus have to say about XNCR?

Argus Research

a year ago

XNCR: Raising target price to $18.00

Estimating The Intrinsic Value Of Xencor, Inc. (NASDAQ:XNCR)

Simply Wall St.

a year ago

Estimating The Intrinsic Value Of Xencor, Inc. (NASDAQ:XNCR)

Xencor (XNCR) Reports Q2 Loss, Misses Revenue Estimates

Zacks

a year ago

Xencor (XNCR) Reports Q2 Loss, Misses Revenue Estimates

Associated Press Finance

a year ago

Xencor: Q2 Earnings Snapshot

Xencor Reports Second Quarter 2024 Financial Results

Business Wire

a year ago

Xencor Reports Second Quarter 2024 Financial Results

Argus Research

a year ago

XNCR: What does Argus have to say about XNCR?

Argus Research

a year ago

XNCR: Raising target price to $21.00

Argus Research

a year ago

XNCR: What does Argus have to say about XNCR?

Xencor (NASDAQ:XNCR) shareholders have endured a 52% loss from investing in the stock five years ago

Simply Wall St.

a year ago

Xencor (NASDAQ:XNCR) shareholders have endured a 52% loss from investing in the stock five years ago

MT Newswires

a year ago

Raymond James Adjusts Price Target on Xencor to $40 From $58, Maintains Strong Buy Rating

MT Newswires

a year ago

BMO Capital Adjusts Xencor's Price Target to $32 From $34, Keeps Outperform Rating

MT Newswires

a year ago

RBC Trims Price Target on Xencor to $31 From $32, Maintains Outperform, Speculative Risk Rating

MT Newswires

a year ago

Wedbush Cuts Price Target on Xencor to $34 From $36, Maintains Outperform Rating

MT Newswires

a year ago

Xencor to Regain Exclusive Global Rights to CD20 x CD3 Bispecific T-Cell Engager

Xencor Regains CD20 x CD3 Bispecific T-Cell Engager

Business Wire

a year ago

Xencor Regains CD20 x CD3 Bispecific T-Cell Engager

Share on Social Networks: